ASC-J9®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals

•Our study provides one possible mechanism why the current ADT eventually fails to suppress prostate cancer (PCa) progression.•ASC-J9®, but not Casodex or Ezalutamide, can suppress prostate cancer stem/progenitor cell invasion.•This potential drug, ASC-J9®, suppresses PCa by killing differentiated PCa cells via EZH2-STAT3 signals and degrading AR.